Similarly, use of an SGLT-2 inhibitor was associated with a lower incidence of cardiovascular death or heart failure in patients without CKD: RR 0.84 (95% CI 0.77–0.91; P < 0.001) (Supplemental Fig. 4 and Table 3). This evidence concerns the gene SLC5A2 and chronic kidney disease.